Sergio Giralt Selected Research

Multiple Myeloma

5/2024	Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
4/2024	Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
4/2024	CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
3/2024	Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
2/2024	Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.
2/2024	Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
1/2024	Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.
12/2023	Acupuncture improves certain aspects of sleep in hematopoietic stem cell transplantation patients: a secondary analysis of a randomized controlled trial.
11/2023	Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
9/2023	Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sergio Giralt Research Topics

Disease

77	Multiple Myeloma 05/2024 - 09/2003
46	Neoplasms (Cancer) 04/2024 - 01/2002
41	Graft vs Host Disease (Graft-Versus-Host Disease) 03/2024 - 01/2002
32	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 01/2002
32	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 08/2004
26	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 01/2002
15	Leukemia 01/2022 - 01/2002
13	Infections 02/2024 - 02/2009
12	Disease Progression 03/2024 - 06/2004
12	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2015 - 01/2000
11	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2024 - 01/2002
11	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2023 - 06/2004
11	Lymphoma (Lymphomas) 01/2021 - 06/2004
7	Bronchiolitis Obliterans Syndrome 01/2022 - 03/2004
6	Residual Neoplasm 05/2024 - 09/2010
6	Neutropenia 02/2024 - 10/2011
5	Cytokine Release Syndrome 03/2023 - 02/2014
5	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022 - 02/2010
4	Agammaglobulinemia (Hypogammaglobulinemia) 02/2024 - 01/2023
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 05/2003
4	Pain (Aches) 01/2020 - 04/2007
3	Cytopenia 01/2023 - 11/2020
3	Viremia 01/2023 - 10/2011
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023 - 11/2020
3	Plasma Cell Leukemia 01/2023 - 10/2006
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2006 - 01/2004
2	Abdominal Obesity 01/2024 - 09/2023
2	Primary Myelofibrosis (Myelosclerosis) 01/2023 - 04/2010
2	cell-associated neurotoxicity 01/2021 - 01/2020
2	Pathologic Complete Response 11/2020 - 08/2004
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 04/2016 - 06/2008

Drug/Important Bio-Agent (IBA)

20	Melphalan (Alkeran)FDA LinkGeneric 12/2020 - 05/2003
15	Lenalidomide (CC 5013)FDA Link 05/2024 - 10/2007
12	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 03/2003
11	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 05/2003
10	Chimeric Antigen ReceptorsIBA 03/2024 - 02/2014
10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 03/2003
10	Rituximab (Mabthera)FDA Link 01/2020 - 04/2003
9	Dexamethasone (Maxidex)FDA LinkGeneric 03/2024 - 06/2011
9	trans-crotonin (CTN)IBA 02/2024 - 12/2011
9	fludarabineIBA 01/2020 - 08/2004
7	Bortezomib (Velcade)FDA Link 03/2024 - 04/2007
6	Busulfan (Busulfex)FDA Link 01/2020 - 03/2003
6	Tyrosine Kinase InhibitorsIBA 04/2012 - 03/2007
6	Imatinib Mesylate (Gleevec)FDA Link 03/2011 - 01/2000
5	B-Cell Maturation AntigenIBA 04/2024 - 11/2020
5	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 09/2003
5	Proteasome InhibitorsIBA 03/2024 - 01/2020
5	Alemtuzumab (Campath)FDA Link 12/2014 - 05/2003
4	ixazomibIBA 03/2024 - 01/2020
4	Monoclonal AntibodiesIBA 11/2023 - 07/2006
4	Phosphotransferases (Kinase)IBA 01/2023 - 08/2006
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2017 - 01/2002
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 12/2014 - 08/2005
4	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2014 - 04/2003
4	SteroidsIBA 12/2009 - 06/2004
3	idecabtagene vicleucelIBA 04/2024 - 03/2023
3	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 04/2024 - 01/2023
3	daratumumabIBA 03/2024 - 03/2023
3	carfilzomibIBA 03/2024 - 02/2023
3	salicylhydroxamic acid (SHAM)IBA 12/2023 - 01/2018
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2023 - 01/2016
3	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2019
3	Calcineurin InhibitorsIBA 01/2022 - 11/2012
3	CytokinesIBA 11/2021 - 06/2009
3	tisagenlecleucelIBA 01/2021 - 01/2020
3	axicabtagene ciloleucelIBA 01/2021 - 01/2020
3	Azacitidine (5 Azacytidine)FDA Link 11/2020 - 05/2009
3	Etoposide (VP 16)FDA LinkGeneric 10/2015 - 05/2003
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 05/2015 - 05/2013
3	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2014 - 01/2002
3	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 06/2013 - 06/2004
3	HLA Antigens (Human Leukocyte Antigens)IBA 03/2013 - 03/2007
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 10/2011 - 06/2004
2	Heme (Haem)IBA 03/2024 - 10/2023
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2023 - 06/2011
2	AntibodiesIBA 11/2023 - 05/2014
2	Immunomodulating AgentsIBA 03/2023 - 01/2020
2	Alkylating AgentsIBA 01/2023 - 04/2003
2	FluoroquinolonesIBA 12/2021 - 10/2014
2	Decitabine FDA Link 01/2021 - 03/2003
2	Ferritins (Ferritin)IBA 11/2020 - 01/2009
2	Surface Antigens (Surface Antigen)IBA 11/2019 - 05/2010
2	defibrotideIBA 03/2016 - 08/2012
2	VaccinesIBA 12/2015 - 08/2010
2	Ifosfamide FDA LinkGeneric 10/2015 - 06/2011

Therapy/Procedure

63	Hematopoietic Stem Cell Transplantation 10/2023 - 01/2003
61	Therapeutics 04/2024 - 01/2003
49	Transplantation 03/2024 - 01/2002
48	Stem Cell Transplantation 09/2023 - 01/2002
36	Cell Transplantation 05/2024 - 12/2007
25	Drug Therapy (Chemotherapy) 12/2023 - 01/2002
15	Homologous Transplantation 01/2023 - 01/2002
6	Autologous Transplantation 01/2019 - 06/2004
6	Hematopoietic Stem Cell Mobilization 01/2017 - 07/2006
5	Salvage Therapy 01/2023 - 06/2004
5	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 06/2011 - 01/2002
4	Immunotherapy 11/2023 - 08/2010
3	Radiotherapy 01/2020 - 05/2007
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 09/2005 - 01/2002